An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).Axel Hauschild, Paul B. Chapman, Jean‐Jacques Grob et al.|Journal of Clinical Oncology|2013Cited by 112
19p13.1 Is a Triple-Negative–Specific Breast Cancer Susceptibility LocusKristen N. Stevens, Thérèse Truong, Heli Nevanlinna et al.|Cancer Research|2012Cited by 108
Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the BreastElinor J. Sawyer, Javier Benı́tez, Rebecca Roylance et al.|PLoS Genetics|2014Cited by 49